ALX Oncology Holdings Inc.
NASDAQ:ALXO
1.29 (USD) • At close February 4, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | ALX Oncology Holdings Inc. |
Symbool | ALXO |
Munteenheid | USD |
Prijs | 1.29 |
Beurswaarde | 68,038,599 |
Dividendpercentage | 0% |
52-weken bereik | 1.19 - 17.825 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Jason W. Lettmann |
Website | https://www.alxoncology.com |
An error occurred while fetching data.
Over ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)